272CT, Commercial Contracts Attorney

Job Code 272CT


Fate Therapeutics’ legal group is seeking a career-oriented attorney with significant experience with drafting and negotiating commercial contracts to provide transactional support for the Company’s operations, with a particular focus on implementing agreements to support clinical operations, manufacturing, and product development. The successful candidate will interact with personnel at all levels of the Company as well as with external parties to prepare, review, and negotiate a range of complex contracts. Effectiveness in this position will require the ability to identify business and legal risks and offer creative solutions, counsel internal business units and negotiate independently with third parties. The successful candidate also must have the ability to work independently with minimal instruction under the supervision of the General Counsel, and must be able to work accurately in a fast-paced environment and maintain a sense of urgency. This is a full-time contract position reporting to the General Counsel, and requires 100% on site work at the Corporate headquarters in San Diego, California. Position will be eligible for conversion to a full-time employee.

Download a PDF of the job description for more details:

View PDF

For consideration send cover letter and curriculum vitae to: careers@fatetherapeutics.com and reference job 272CT.

About Fate Therapeutics, Inc.

Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product candidate pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.